Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Rafii, Arash ^a,g   Stoeckle, Eberhard ^b   Jean Laurent, Mehdi ^a   Ferron, Gwenael ^a   Morice, Philippe ^c   Houvenaeghel, Gilles ^d   Lecuru, Fabrice ^e   Leblanc, Eric ^f   Querleu, Denis ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ABDOMINAL HYSTERECTOMY; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; APPENDECTOMY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FISTULA; FRANCE; HEMATOMA; HEMOPERITONEUM; HUMAN; HYPOALBUMINEMIA; ILEUS; INTESTINE OBSTRUCTION; LAPAROTOMY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORBIDITY; OMENTECTOMY; OVARY CANCER; PANCREATITIS; PELVIS LYMPHADENECTOMY; PERITONITIS; POSTOPERATIVE PERIOD; SALPINGOOOPHORECTOMY; SEPSIS; SEROMA; SIGMOIDOSCOPY; SPLENECTOMY; SURGICAL MORTALITY; THROMBOCYTE COUNT; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84864224052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039415     Document Type: Article

References (25)

1. Schwartz PE, (2008) Cytoreductive surgery in the management of ovarian cancer. Oncology 22: 1025-33.
2. Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, et al. (2003) Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 15;21 10 Supplpp. 129s-132s.
3. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, et al. (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9(7): 1138-50.
4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, et al. (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 15 115(6): 1234-44.
5. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, et al. (2010) Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 119(2): 259-64.
6. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103(2): 559-64.
7. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, et al. (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 21(4): 750-5.
8. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1): 26-31.
9. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943-53.
10. Chi DS, Schwartz PE, (2008) Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol 111(3): 391-9.
11. Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, et al. (2010) The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119(1): 38-42.
12. Look M, Chang D, Sugarbaker PH, (2003) Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 13(6): 764-70.
13. Chi DS, Abu-Rustum NR, Sonoda Y, Awtrey C, Hummer A, et al. (2004) Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 191(4): 1138-45.
14. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70(2): 209-62.
15. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, et al. (2010) Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 120(1): 23-8.
16. Gerestein CG, Damhuis RA, Burger CW, Kooi GS, (2009) Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol 114: 523-7.
17. Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, et al. (2010) Quality of care in advanced ovarian cancer: the importance of provider specialty.Gynecol Oncol. 117(1): 18-22.
18. Chéreau E, Rouzier R, Gouy S, Ferron G, Narducci F, et al. (2011) 19. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur J Surg Oncol. 37(2): 175-80.
19. Chereau E, Ballester M, Selle F, Cortez A, Pomel C, et al. (2009) Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG 116: 1062-8.
20. Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W, (2008) Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 109(2): 303-7.
21. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, et al. (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99: 608-14.
22. Richardson DL, Mariani A, Cliby WA, (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2): 667-72.
23. Bristow RE, Chi DS, (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103(3): 1070-6.
24. Kang S, Nam BH, (2009) Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 16: 2315-20.
25. Chereau E, Ballester M, Selle F, Cortez A, Darai E, Rouzier R, (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202: 178 e1-178 e10.